Arcutis Biotherapeutics, Inc. ARQT Other Commercial Liabilities
Other Commercial Liabilities at other companies
Other financials
Where this comes from
Reported directly by Arcutis Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Arcutis Biotherapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arcutis Biotherapeutics, Inc.'s other commercial liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arcutis Biotherapeutics, Inc.'s other commercial liabilities?
- Arcutis Biotherapeutics, Inc. (ARQT) reported other commercial liabilities of $136.96M in Q1 2026.
- How has Arcutis Biotherapeutics, Inc.'s other commercial liabilities changed year-over-year?
- Arcutis Biotherapeutics, Inc.'s other commercial liabilities increased by 108.3% year-over-year, from $65.76M to $136.96M.
- What is the long-term trend for Arcutis Biotherapeutics, Inc.'s other commercial liabilities?
- Over 5 years (2020 to 2025), Arcutis Biotherapeutics, Inc.'s other commercial liabilities has grown at a 49.7% compound annual growth rate (CAGR), from $15.46M to $116.31M.